Business
Presents Moditope Data at Immunotherapy Conference
Presents Moditope Data at Immunotherapy Conference.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2969Q Scancell Holdings Plc 11 September 2017 \n\n11 September 2017\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell Presents Moditope® Data at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference \n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that it has presented data on the Company's Moditope® platform at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in Mainz, Germany, 6-9 September 2017.\n \nScancell's Moditope® platform stimulates powerful anti-tumour T-cell responses against citrullinated peptides which destroy tumours without toxicity.\n \nProf. Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy, University of Nottingham, presented two posters on Friday 8 September 2017 at 6.15pm CET, in poster session B.\n \nProf. Durrant commented: \n \n\"We were pleased to be selected to present our latest data on Moditope® at this year's prestigious International Cancer Immunotherapy Conference, showing that our lead product from the Moditope® platform, Modi-1, induced strong anti-tumour immunity in pancreatic, lung, ovarian and melanoma models with up to 100% survival.\n \n\"Our poster in collaboration with ISA Pharmaceuticals showed that Modi-1 conjugated to synthetic TLR1/2 agonists generated an anti-tumour response at up to 100-fold lower doses than Modi-1 alone and that these conjugated peptides induced a memory response against tumour re-challenge. \n \n\"These results suggest that Modi-1 conjugated directly to TLR agonists could be a powerful new approach to the treatment of cancer.\"\n \nBoth posters will be made available on the Investor section of the Company's website:\nhttps://www.scancell.co.uk/investors \n \n \nFor Further Information: \n \n\n\n\n\nDr John Chiplin, Executive Chairman\nDr Richard Goodfellow, CEO\n\n\nScancell Holdings Plc\n \n\n\n+1 858 900 2646\n+44 (0) 20 3727 1000\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFreddy Crossley (Corporate Finance)\nTom Salvesen (Corporate Broking)\n\n\nPanmure Gordon & Co\n\n\n+44 (0) 20 7886 2500\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMo Noonan/Simon Conway\n\n\nFTI Consulting\...